Cancer treatment and research communications · 2026
Distinct clinic and ultrasound imaging manifestations associated with HER2-low expression in triple-negative breast cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lyu Maohua, Wu Jiarui, Xu Zeyan, Li Chunyan, Liu Yu, Huang Xu, Li Qian, Xie Yu, Lin Xi, Huang Chunwang, Liu Zaiyi, Wang Ying, Shi Zhenwei
Аннотация
BACKGROUND: To determine whether HER2-low tumors exhibit a particular subtype among individuals with triple-negative breast cancer (TNBC).
METHODS: This multicenter study enrolled 539 patients diagnosed with TNBC who underwent surgery after neoadjuvant chemotherapy. Comparative analyses of clinicopathological factors, qualitative ultrasound imaging characteristics (BI-RADS), quantitative ultrasound imaging characteristics (Radiomics), and clinical outcomes, including pathologic complete response (pCR), event-free survival (EFS), and overall survival (OS), were conducted between patients with HER2-low and HER2-0.
RESULTS: Patients with low Ki67 expression were more common in HER2-low patients as compared to HER2-0 patients. Based on ultrasound BI-RADS characteristics, the difference in vascularity pattern was observed between the two different HER2 status, where HER2-0 tumors presented more avascularity (12.0%vs. 6.3%). Ultrasound radiomics characteristics revealed the differences in shape, minimum voxel intensity, and texture. In the overall cohort, no significant association was found between HER2-low expression and pCR, EFS, or OS (p > 0.05). Compared to HER2-0, HER2-low patients exhibited a lower pCR rate among individuals with low T stage. Conversely, in patients with high T stage, the pCR rate was higher, although this finding did not achieve statistical significance (p = 0.065). Among non-pCR patients, HER2-low status was also associated with improved EFS.
CONCLUSION: Compared with HER2-0, HER2-low tumors are distinct in clinicopathological factors, ultrasound imaging characteristics, response to neoadjuvant chemotherapy, and prognosis. Our results provided a better understanding of HER2-low status in TNBC by detailed subgroup analysis, which can offer valuable insights for managing HER2-low patients in clinical practice.
METHODS: This multicenter study enrolled 539 patients diagnosed with TNBC who underwent surgery after neoadjuvant chemotherapy. Comparative analyses of clinicopathological factors, qualitative ultrasound imaging characteristics (BI-RADS), quantitative ultrasound imaging characteristics (Radiomics), and clinical outcomes, including pathologic complete response (pCR), event-free survival (EFS), and overall survival (OS), were conducted between patients with HER2-low and HER2-0.
RESULTS: Patients with low Ki67 expression were more common in HER2-low patients as compared to HER2-0 patients. Based on ultrasound BI-RADS characteristics, the difference in vascularity pattern was observed between the two different HER2 status, where HER2-0 tumors presented more avascularity (12.0%vs. 6.3%). Ultrasound radiomics characteristics revealed the differences in shape, minimum voxel intensity, and texture. In the overall cohort, no significant association was found between HER2-low expression and pCR, EFS, or OS (p > 0.05). Compared to HER2-0, HER2-low patients exhibited a lower pCR rate among individuals with low T stage. Conversely, in patients with high T stage, the pCR rate was higher, although this finding did not achieve statistical significance (p = 0.065). Among non-pCR patients, HER2-low status was also associated with improved EFS.
CONCLUSION: Compared with HER2-0, HER2-low tumors are distinct in clinicopathological factors, ultrasound imaging characteristics, response to neoadjuvant chemotherapy, and prognosis. Our results provided a better understanding of HER2-low status in TNBC by detailed subgroup analysis, which can offer valuable insights for managing HER2-low patients in clinical practice.